<DOC>
	<DOCNO>NCT02365402</DOCNO>
	<brief_summary>The aim interferon therapy HBeAg negative chronic hepatitis B make patient obtain immune control hepatitis B virus define sustained viral response treatment . However target could get patient keep HBV DNA positive interferon treatment offend relapse treatment withdraw . In trail , entecavir add patient HBV DNA load ≥1000copies/ml 3 month peginterferon alpha 2a treatment , efficacies combine treatment evaluate rate sustain viral response 48 week treatment 24 week follow .</brief_summary>
	<brief_title>Efficacies Entecavir Add HBeAg Negative Patients With HBV DNA Positive During Peginterferon Alpha 2a Treatment</brief_title>
	<detailed_description>HBeAg negative patient HBV DNA load ≥1000copies/ml 3 month peginterferon alpha 2a treatment would randomize enrolled two group , Interventional group , patient receive entecavir combine peginterferon alpha 2a treatment 48 week follow 24 week . Patients control group continue treat peginterferon alpha 2a 48 week follow 24 week treatment . Serum HBV DNA load , HBsAg/anti-HBs level , HBeAg/anti-HBe test enrollment every 3 month treatment course . Parameters Liver kidney function , liver ultrasound examination test interval 1-3 month . The efficacy combine therapy evaluate rate sustain viral response 48 week treatment 24 week follow compare control group .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<criteria>HBeAg negative patient HBV DNA load ≥1000copies/ml 3 month peginterferon a2a treatment Active consumption alcohol and/or drug Coinfection human immunodeficiency virus , hepatitis C virus , hepatitis D virus History autoimmune hepatitis Psychiatric disease Evidence neoplastic disease liver</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>chronic hepatitis B</keyword>
	<keyword>peginterferon</keyword>
	<keyword>sustain viral response</keyword>
	<keyword>entecavir</keyword>
	<keyword>HBeAg</keyword>
</DOC>